{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:16:07Z","timestamp":1777652167715,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,20]]},"DOI":"10.7759\/cureus.29379","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T01:54:53Z","timestamp":1663725293000},"source":"Crossref","is-referenced-by-count":3,"title":["Overlapping Autoimmune Neurological Syndrome: A Case Report of Triple-Positive Antibody"],"prefix":"10.7759","author":[{"given":"Kyle","family":"Bonner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Aboul Nour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anza B","family":"Memon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2014.883501","article-title":"A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica","volume":"47","author":"Iyer A","year":"2014","unstructured":"Iyer A, Elsone L, Appleton R, Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity. 2014, 47:154-61. 10.3109\/08916934.2014.883501","journal-title":"Autoimmunity"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.01.007","article-title":"Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis","volume":"20","author":"Fan S","year":"2018","unstructured":"Fan S, Xu Y, Ren H, et al.. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Mult Scler Relat Disord. 2018, 20:144-52. 10.1016\/j.msard.2018.01.007","journal-title":"Mult Scler Relat Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer MJ","year":"2014","unstructured":"Titulaer MJ, H\u00f6ftberger R, Iizuka T, et al.. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014, 75:411-28. 10.1002\/ana.24117","journal-title":"Ann Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102205","article-title":"Anti-MOG and anti-AQP4 positive neuromyelitis optica spectrum disorder in a patient with myasthenia gravis","volume":"44","author":"Bates M","year":"2020","unstructured":"Bates M, Chisholm J, Miller E, Avasarala J, Guduru Z. Anti-MOG and anti-AQP4 positive neuromyelitis optica spectrum disorder in a patient with myasthenia gravis. Mult Scler Relat Disord. 2020, 44:102205. 10.1016\/j.msard.2020.102205","journal-title":"Mult Scler Relat Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09498-4","article-title":"Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review","volume":"268","author":"Chamberlain JL","year":"2021","unstructured":"Chamberlain JL, Huda S, Whittam DH, Matiello M, Morgan BP, Jacob A. Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. J Neurol. 2021, 268:1643-64. 10.1007\/s00415-019-09498-4","journal-title":"J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015, 14:1023-36. 10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2014.07.036","article-title":"Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature","volume":"125","author":"Ikeguchi R","year":"2014","unstructured":"Ikeguchi R, Shimizu Y, Suzuki S, et al.. Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature. Clin Neurol Neurosurg. 2014, 125:217-21. 10.1016\/j.clineuro.2014.07.036","journal-title":"Clin Neurol Neurosurg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius S","year":"2012","unstructured":"Jarius S, Paul F, Franciotta D, et al.. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler. 2012, 18:1135-43. 10.1177\/1352458511431728","journal-title":"Mult Scler"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S136723","article-title":"Clinical features of limbic encephalitis with LGI1 antibody","volume":"13","author":"Wang M","year":"2017","unstructured":"Wang M, Cao X, Liu Q, Ma W, Guo X, Liu X. Clinical features of limbic encephalitis with LGI1 antibody. Neuropsychiatr Dis Treat. 2017, 13:1589-96. 10.2147\/NDT.S136723","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite MI","year":"2012","unstructured":"Leite MI, Coutinho E, Lana-Peixoto M, et al.. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 2012, 78:1601-7. 10.1212\/WNL.0b013e31825644ff","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1148\/rg.302095131","article-title":"Clinical and radiologic review of the normal and abnormal thymus: pearls and pitfalls","volume":"30","author":"Nasseri F","year":"2010","unstructured":"Nasseri F, Eftekhari F. Clinical and radiologic review of the normal and abnormal thymus: pearls and pitfalls. Radiographics. 2010, 30:413-28. 10.1148\/rg.302095131","journal-title":"Radiographics"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00543-w","article-title":"Autoantibodies in neurological disease","volume":"21","author":"Pr\u00fcss H","year":"2021","unstructured":"Pr\u00fcss H. Autoantibodies in neurological disease. Nat Rev Immunol. 2021, 21:798-813. 10.1038\/s41577-021-00543-w","journal-title":"Nat Rev Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman CL","year":"2018","unstructured":"Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018, 182:29-45. 10.1111\/bjh.15232","journal-title":"Br J Haematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato V","year":"2016","unstructured":"Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016, 73:1342-8. 10.1001\/jamaneurol.2016.1637","journal-title":"JAMA Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan R","year":"2017","unstructured":"Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017, 56:185-96. 10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer MJ","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, et al.. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013, 12:157-65. 10.1016\/S1474-4422(12)70310-1","journal-title":"Lancet Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/111695-overlapping-autoimmune-neurological-syndrome-a-case-report-of-triple-positive-antibody","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:23Z","timestamp":1707507563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/111695-overlapping-autoimmune-neurological-syndrome-a-case-report-of-triple-positive-antibody"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.29379","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}